Formulation Development
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
BriaCell Therapeutics Corp. recently announced the US FDA has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT, for the treatment of metastatic breast cancer…
Artelo Biosciences Reports Positive Preclinical Results for Lead Program in Cancer-Related Cachexia
Artelo Biosciences, Inc. recently announced ART27.13, a peripherally selective G-Protein Coupled Receptor (GPCR) full agonist currently in clinical development for cancer-related anorexia, shows promising preclinical…
ChemoCentryx Reports PK & PD Results From Ongoing Phase 1 Trial of Orally Administered PD-L1 Inhibitor
ChemoCentryx, Inc. recently announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 clinical study of…
Geocann & Averix Bio Form Strategic Partnership to Supply Global Marketplace With Pharmaceutical API Phytocannabinoid Ingredients Formulated With Proven Delivery System
Geocann recently announced a strategic partnership with Averix Bio that will bring US-produced API phytocannabinoid ingredients and clinically proven bioavailable formulations to the global marketplace.…
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency & ENPP1 Deficiency
Inozyme Pharma, Inc. recently announced the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency…
Caladrius Biosciences Treats First Patient in the Phase 1b Trial for the Treatment of Diabetic Kidney Disease
Caladrius Biosciences, Inc. recently announced the first patient has been treated in its Phase 1b open-label, proof-of-concept study of CLBS201 for the treatment of diabetic…
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for Anti-Infectives
Recce Pharmaceuticals Limited recently announced the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, Anti-Virus Agent and Method…
LIXTE Biotechnology Announces Preclinical Results of its Collaboration With the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity
LIXTE Biotechnology Holdings, Inc. recently announced Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data from promising drug combinations of LIXTE’s lead clinical…
Venomtech Announces New Drug Development Collaboration With Charles River
Venomtech is collaborating with Charles River Laboratories, International Inc. to help drug developers explore venom-derived compounds for a wide range of….
WHITE PAPER: Controlled Synthesis of Lipid Nanoparticles Using the Automated Nanoparticle System
Particle Works’ leading microfluidic technology offers a unique automated nanoparticle generation platform for the production of homogeneous, controllable, and reproducible LNPs….
Matinas BioPharma & BioNTech Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
Matinas BioPharma and BioNTech SE recently announced they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and….
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
Krystal Biotech, Inc. recently announced it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study,…
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Diffusion Pharmaceuticals Inc. recently announced the final participant has completed dosing in its Altitude Trial. The Altitude Trial is a double-blind, randomized, placebo-controlled crossover study,…
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
Eton Pharmaceuticals, Inc. recently announced it has received final approval from the US FDA for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of….
AEON Biopharma Completes Enrollment in Phase 2 Clinical Study
AEON Biopharma, Inc. recently announced the completion of patient enrollment in the Phase 2 clinical study of ABP-450 (prabotulinumtoxinA) for the treatment of cervical dystonia.…
VectorBuilder to Expand With $500-Million Gene Delivery Research & Manufacturing Campus
VectorBuilder Inc. recently announced the construction of a new R&D and manufacturing center in Guangzhou, China. The Gene Delivery Research and Manufacturing Campus will significantly expand…
Context Therapeutics Announces Encouraging Preclinical Data From Two Programs
Context Therapeutics Inc. recently announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s…
Enteris BioPharma Highlighted as Game Changer in Special Feature on Innovative Technologies for Improving Drug Solubility & Bioavailability
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data From Phase 1b/2a Trial
VYNE Therapeutics Inc. recently announced positive efficacy results from the Phase 1b segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of…
FREEZE-DRYING MICROSCOPY - Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques
Paul Matejtschuk, PhD, Prof Yvonne Perrie, and Robert Gurney, PhD, say FDM is being used to analyze the most challenging formulations that require sophisticated stabilization methods. By altering and adapting the three main freeze-drying stages to specific formulations, researchers are providing the tools needed for the pharma industry to improve its drug development processes and maintain drug stability when scaling up to production.
